GLYC - GlycoMimetics picks internal candidate for chief medical officer

GlycoMimetics ([[GLYC]] -10.0%) promoted Eric Feldman, M.D., to SVP and Chief Medical Officer; Dr. Feldman joined the company in 2019 and was earlier VP, Global Clinical Development."Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders, and in the past two years, has established himself as a leader in our management group as well as in the trenches with our clinical operations team," CEO Rachel King commented.Most recently, Dr. Feldman served as Chief Medical Officer at Amphivena Therapeutics.Dr. Helen Thackray, M.D. F.A.A.P., SVP, Clinical Development and Chief Medical Officer, has decided to leave the company to pursue another opportunity.

For further details see:

GlycoMimetics picks internal candidate for chief medical officer